Cardiometabolic syndrome is a constellation of maladaptive cardiovascular, renal, metabolic, prothrombotic, and inflammatory abnormalities leading to increased risk of developing cardiovascular diseases (CVD). Currently, the combined impact of obesity, diabetes, and CVD is the biggest health problem worldwide with leading cause of mortality despite therapeutic advances. The knowledge of the prognostic relationship between metabolic risk factors and CVD is must for physicians or healthcare providers for optimized treatment strategies to prevent and/or delay disease progression.
The most comprehensive continuing medical education offered at our 3rd ASIA-PACIFIC CARDIOMETABOLIC SUMMIT on 25th & 26th November 2017 at Hotel The Leela, Mumbai will allow front-line doctors to stay advanced on best practices, research, and new advances to prevent, delay, and manage cardiometabolic risk. The meeting curriculum will provide the most effective, current strategies for the prevention, diagnosis, and management of cardiometabolic diseases and related comorbidities in daily practice.
This event is involved in a comprehensive educational programme for cardiologists, endocrinologists, hypertension specialists and other related healthcare professionals involved in the treatment of patients at risk for cardiometabolic syndrome and will provide a chance for direct interaction with participants and the exchange of ideas and knowledge will be facilitated.
BENEFITS OF ASIA-PACIFIC CARDIOMETABOLIC SUMMIT